<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Patient demographics and disease characteristics at baseline (Safety population)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>BTH1677/
     <break/>Bevacizumab/Carboplatin/
     <break/>Paclitaxel
     <break/>(
     <italic>N</italic> = 59)
    </th>
    <th>Bevacizumab/
     <break/>Carboplatin/
     <break/>Paclitaxel
     <break/>(
     <italic>N</italic> = 30)
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="3">Age (years)</td>
   </tr>
   <tr>
    <td> Median (range)
     <sup>a</sup>
    </td>
    <td>59 (43, 76)</td>
    <td>58 (28, 75)</td>
   </tr>
   <tr>
    <td colspan="3">Sex, n (%)</td>
   </tr>
   <tr>
    <td> Male</td>
    <td>26 (44.1)</td>
    <td>14 (46.7)</td>
   </tr>
   <tr>
    <td> Female</td>
    <td>33 (55.9)</td>
    <td>16 (53.3)</td>
   </tr>
   <tr>
    <td colspan="3">Race, n (%)</td>
   </tr>
   <tr>
    <td> White</td>
    <td>57 (96.6)</td>
    <td>30 (100.0)</td>
   </tr>
   <tr>
    <td> Black</td>
    <td>1 (1.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Asian or Pacific Islander</td>
    <td>1 (1.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="3">ECOG Performance Status, n (%)</td>
   </tr>
   <tr>
    <td> 0</td>
    <td>31 (52.5)</td>
    <td>20 (66.7)</td>
   </tr>
   <tr>
    <td> 1</td>
    <td>28 (47.5)</td>
    <td>10 (33.3)</td>
   </tr>
   <tr>
    <td colspan="3">Disease stage at randomization</td>
   </tr>
   <tr>
    <td> Stage IIIB</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Stage IV</td>
    <td>59 (100.0)</td>
    <td>30 (100.0)</td>
   </tr>
   <tr>
    <td colspan="3">Time from initial tumor diagnosis to diagnosis of stage IIIB/IV NSCLC (days)
     <sup>b</sup>
    </td>
   </tr>
   <tr>
    <td> Median (range)</td>
    <td>0 (0, 3158)</td>
    <td>0 (0, 0)</td>
   </tr>
   <tr>
    <td colspan="3">Time from diagnosis of stage IIIB/IV NSCLC to randomization (days)
     <sup>c</sup>
    </td>
   </tr>
   <tr>
    <td> Median (range)</td>
    <td>18 (1, 168)</td>
    <td>17.5 (7, 77)</td>
   </tr>
   <tr>
    <td colspan="3">Time from initial tumor diagnosis to randomization (days)
     <sup>d</sup>
    </td>
   </tr>
   <tr>
    <td> Median (range)</td>
    <td>20 (1, 3171)</td>
    <td>17.5 (7, 77)</td>
   </tr>
   <tr>
    <td colspan="3">Prior cancer treatment, n (%)</td>
   </tr>
   <tr>
    <td> Radiotherapy</td>
    <td>2 (3.4)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Surgery</td>
    <td>8 (13.6)</td>
    <td>2 (6.7)</td>
   </tr>
   <tr>
    <td> Chemotherapy, hormonal, or other
     <sup>e</sup>
    </td>
    <td>2 (3.4)</td>
    <td>0</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Abbreviations: ECOG</italic> Eastern Cooperative Oncology Group, 
   <italic>N</italic> overall sample size, 
   <italic>n</italic> number of patients, 
   <italic>NSCLC</italic> non-small cell lung cancer
  </p>
  <p>
   <sup>a</sup>Inclusion criteria restricted patients to 18 to 75 years of age but one 76-year-old patient was inadvertently enrolled in the study
  </p>
  <p>
   <sup>b</sup>Time from initial tumor diagnosis to diagnosis of Stage IIIB/IV NSCLC = Stage IIIB/IV diagnosis date - initial tumor diagnosis date
  </p>
  <p>
   <sup>c</sup>Time from diagnosis of Stage IIIB/IV NSCLC to randomization = Date of randomization - Stage IIIB/IV diagnosis date
  </p>
  <p>
   <sup>d</sup>Time from initial tumor diagnosis to randomization = Date of randomization –initial tumor diagnosis date
  </p>
  <p>
   <sup>e</sup>Two patients in the BTH1677 arm received prior chemotherapy for lung cancer. Both patients were previous responders and received the prior chemotherapy greater than 6 months prior to enrollment
  </p>
 </table-wrap-foot>
</table-wrap>
